IN2015DN01371A - - Google Patents

Download PDF

Info

Publication number
IN2015DN01371A
IN2015DN01371A IN1371DEN2015A IN2015DN01371A IN 2015DN01371 A IN2015DN01371 A IN 2015DN01371A IN 1371DEN2015 A IN1371DEN2015 A IN 1371DEN2015A IN 2015DN01371 A IN2015DN01371 A IN 2015DN01371A
Authority
IN
India
Prior art keywords
ifn
fusion protein
present
protein
interferon
Prior art date
Application number
Other languages
English (en)
Inventor
Yong Soo Bae
Seung Ho Hong
Young Hoon Kim
Seung Soo Han
Jin Kim
Original Assignee
Jw Creagene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jw Creagene Inc filed Critical Jw Creagene Inc
Publication of IN2015DN01371A publication Critical patent/IN2015DN01371A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
IN1371DEN2015 2012-08-13 2013-08-07 IN2015DN01371A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20120088610 2012-08-13
PCT/KR2013/007136 WO2014027789A1 (ko) 2012-08-13 2013-08-07 세포질 잔류성 세포막 투과 펩타이드 및 폴리에틸렌글리콜이 결합된 인터페론 알파 융합 단백질

Publications (1)

Publication Number Publication Date
IN2015DN01371A true IN2015DN01371A (ja) 2015-07-03

Family

ID=50685640

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1371DEN2015 IN2015DN01371A (ja) 2012-08-13 2013-08-07

Country Status (6)

Country Link
US (1) US9682152B2 (ja)
JP (1) JP6010227B2 (ja)
KR (1) KR102012025B1 (ja)
CN (1) CN104583240B (ja)
IN (1) IN2015DN01371A (ja)
WO (1) WO2014027789A1 (ja)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104987381B (zh) * 2015-06-11 2018-11-27 吉林大学 重组正电荷多肽干扰素及在抗肿瘤和抗病毒治疗中的应用
EP4034146A4 (en) * 2019-09-26 2024-03-06 Orionis Biosciences Inc CONJUGATED CHIMERIC PROTEINS
KR20230099956A (ko) * 2021-12-28 2023-07-05 제이더블유크레아젠 주식회사 면역세포에 항원을 전달하기 위한 폴리펩타이드

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1495045B1 (en) * 2002-03-29 2009-09-02 Creagene, Inc. Cytoplasmic transduction peptides and uses thereof
AU2006281498A1 (en) * 2005-08-15 2007-02-22 F. Hoffmann-La Roche Ag PEG-IFN alpha and ribavirin for HBV treatment
WO2008157367A1 (en) * 2007-06-15 2008-12-24 Genzyme Corporation Fusion proteins containing two tgf-beta binding domains of tgf-beta type ii receptor
US20090286725A1 (en) * 2008-05-15 2009-11-19 Fibrex Medical Research & Development Gmbh Peptides and derivatives thereof, the manufacturing thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition
KR101183826B1 (ko) * 2009-03-27 2012-09-18 제이더블유중외제약 주식회사 인터페론-알파 및 세포질 잔류성 세포막 투과 펩타이드를 포함하는 ＩＦＮ-α 융합 단백질
EP2412730B1 (en) * 2009-03-27 2014-09-10 JW Pharmaceutical Corporation Interferon-alpha (ifn-alpha ) fused protein having ifn-alpha and cytoplasmic transduction peptide (ctp)
CN101942026B (zh) * 2010-10-14 2014-08-27 成都正能生物技术有限责任公司 长效干扰素融合蛋白及其用途

Also Published As

Publication number Publication date
CN104583240A (zh) 2015-04-29
WO2014027789A1 (ko) 2014-02-20
US9682152B2 (en) 2017-06-20
KR102012025B1 (ko) 2019-08-19
KR20150063375A (ko) 2015-06-09
JP2015526084A (ja) 2015-09-10
US20150202312A1 (en) 2015-07-23
CN104583240B (zh) 2017-11-28
JP6010227B2 (ja) 2016-10-19

Similar Documents

Publication Publication Date Title
NZ749962A (en) Pegylated porcine interferon and methods of use thereof
MX2019011215A (es) Ácidos nucleicos que codifican proteínas asociadas a crispr y usos de los mismos.
PH12019501414A1 (en) Amino acid compositions and methods for the treatment of liver diseases
ZA202002094B (en) Trispecific proteins and methods of use
WO2017058892A3 (en) Methods and compositions for antibody-evading virus vectors
TW201613958A (en) MIC-1 fusion proteins and uses thereof
EP2528934A4 (en) AROMATIC-CATIONIC PEPTIDES AND USES THEREOF
MX2018013981A (es) Productos farmaceuticos peptidicos mejorados para la resistencia a la insulina.
MY196882A (en) Recombinant binding proteins and their use
IL212184A (en) Conditional expression vector of protein (s) acting as immunomodulator (s), engineered training cells, their pharmaceutical composition and their use in drug preparation
WO2014145159A3 (en) Charge-engineered antibodies or compositions of penetration-enhanced targeting proteins and methods of use
EA200602137A1 (ru) Гидрогелевые препараты интерферона
GB2496337A (en) Combination pharmaceutical composition and methods of treating diseases or conditions associated with neurodegenerative diseases
MX2021008207A (es) Proteínas de fusión multifuncionales y usos de las mismas.
WO2015031726A3 (en) Engineered primate l-methioninase for therapeutic purposes
MX2014004814A (es) Compuestos y metodos para mejorar las respuestas inmunes innatas.
WO2012083302A3 (en) Compositions and methods for the treatment or prevention of human adenovirus-36 infection
PH12017500450A1 (en) Flavivirus virus like particle
IN2014DN06920A (ja)
MX2013011411A (es) Tratamiento para infeccion por el virus de hepatitis b solo o en combinacion con el virus de hepatitis delta y enfermedades hepaticas asociadas.
IN2015DN01371A (ja)
EP3362048A4 (en) COMPOSITION FOR INTRAORAL ADMINISTRATION OF PEPTIDES AND BIOLOGICALLY ACTIVE PROTEINS
IN2014CN00510A (ja)
BR112014028951A2 (pt) peptídeos ledgf e formulações dos mesmos para tratamento de distúrbios degenerativos
MX2021001361A (es) Composicion liquida de fibrinogeno humano.